Viridian Therapeutics Q3 2026: Lumvoa Launch Blows Past Revenue Estimates
As seen on the 24/7 Wall St. homepage on November 4, 2026.
Lumvoa's first quarter on the market brought in $24.7 million in net product revenue, far exceeding expectations against a $4.7 million total revenue consensus. More than 100 patients are already on therapy, pressuring Amgen's Tepezza, and management says the same commercial build supports an elegrobart launch after a BLA submission planned for Q1 2027.
Continue ReadingShow less
Lumvoa, Viridian's thyroid eye disease treatment, generated $24.7 million in net product revenue in its first quarter of commercial sales, far exceeding expectations. That single product line drove total reported revenue well above the consensus estimate. It is the kind of debut that shifts how investors think about a company's trajectory.
On the bottom line, the GAAP loss per share came in at $0.81, beating expectations. The net loss did widen to $101.21 million from a year ago, though that comparison is distorted by a one-time license payment that inflated Q3 2025 results. SG&A expenses rose as the company built out the commercial infrastructure needed to support the launch.
More than 100 patients are already on Lumvoa therapy, and management is explicitly framing that commercial build as a shared asset. CEO Steve Mahoney said the company is encouraged by the strength of the early launch, adding that the same infrastructure should support a potential elegrobart launch with limited incremental investment, keeping the cost of the next product entry meaningfully lower than starting from scratch.
Sponsored
Elegrobart is a subcutaneous anti-IGF-1R antibody also targeting thyroid eye disease, and a BLA submission is planned for Q1 2027. The planned autoinjector format, with at-home dosing on four-week and eight-week schedules, would differentiate it from intravenous options. A permanent J-code for Lumvoa also takes effect January 1, 2027, which should ease reimbursement friction and support continued patient uptake.
Beyond those two programs, Viridian expects to share phase 1 healthy volunteer data for VRDN-008, its bispecific FcRn inhibitor, in Q4 2026, alongside development plans for its broader FcRn portfolio. The company also plans to initiate a first-in-human trial of VRDN-292, its anti-TSHR antibody, in Graves' disease patients before year-end. Management said existing cash and anticipated revenues from Lumvoa and elegrobart are expected to fund operations through profitability.
Mentioned: VRDN